PhRMA

JANUARY 5, 2023

New research published in the American Journal of Managed Care (AJMC) underscores the critical role that medicines play in improving health and reducing disease complications and other, often costly, medical care and services. The study finds that since curative direct-acting antiviral medications for hepatitis C were approved in 2013, even after factoring in the cost of treatment, Medicaid has saved an estimated $15 billion in avoided health care costs and nearly 285,000 Medicaid enrollees are

211

211

Drug Topics

JANUARY 5, 2023

List prices of 450 medications have increased 5% overall at the beginning of 2023. More price hikes are expected.

212

212

Pharmacy Times

JANUARY 5, 2023

The protein, called suPAR, has long been known to be a biomarker for poor outcomes and disease progression in both kidney disease and cardiovascular disease.

Immunization 132

Immunization 132

Drug Topics

JANUARY 5, 2023

Patients with psoriasis seem to suffer more in the wintertime when flare-ups are much more common.

201

201

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

JANUARY 5, 2023

Big pharma companies have become more measured in their risk taking, with mergers and acquisitions gradually giving way to joint ventures and partnerships.

132

132

Drug Topics

JANUARY 5, 2023

Following certification, brick-and-mortar pharmacies will be able to provide the medication to patients.

FDA 187

FDA 187

STAT

JANUARY 5, 2023

SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies to treat autoimmune diseases and cancer, is now planning to cut back on both jobs and experimental drugs after an early end to a deal with Janssen. The setback, announced Thursday, will cut the company’s size to 220 workers by the end of the first quarter of this year.

Immunization 126

Immunization 126

Pharmacy Times

JANUARY 5, 2023

The opportunity to provide non-invasive colorectal cancer screening and education to patients is undoubtedly a role that pharmacists can fill.

132

132

Fierce Healthcare

JANUARY 5, 2023

Teladoc unveils new app integrating services for primary care and mental health, expands Spanish language offerings. hlandi. Thu, 01/05/2023 - 16:07.

124

124

Pharmacy Times

JANUARY 5, 2023

An overview of current theses and research surrounding the pathogenesis, presentation, and treatment of COVID-19 in children.

139

139

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

JANUARY 5, 2023

As 2023 begins, health care providers in the United States must make health records more easily available or risk losing Medicare funding under the 21st Century Cures Act. While this is a win for patients, providers, and researchers, the legislation’s failure to include dental care ignores the crucial link between oral health and overall health.

105

105

Pharmacy Times

JANUARY 5, 2023

The overall trend of declining body mass index was associated with a higher risk of developing dementia.

139

139

STAT

JANUARY 5, 2023

ANNECY, FRANCE — At first blush, the deal was hailed as a breakthrough. Last fall, Novartis agreed to license a best-selling cancer drug so that generic companies could make copies for distribution to 44 low- and middle-income nations, marking the first time a voluntary license was arranged for a cancer medicine. Until then, such deals typically involved drugs for infectious diseases, such as HIV and hepatitis C.

104

104

Pharmacy Times

JANUARY 5, 2023

A panel of medical experts discuss supportive care needs for patients with myelodysplastic syndrome.

139

139

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

JANUARY 5, 2023

Commonwealth Fund: Medicare inpatient spending concentrated among 2 systems in most regions. rking. Thu, 01/05/2023 - 15:07.

130

130

STAT

JANUARY 5, 2023

For only the second time since launching nearly two years ago, the AMR Action Fund has made another investment in a fledgling European biotech company as it tries to underwrite efforts to develop badly needed medicines for combating antibiotic resistance. In its latest move, the fund is providing $7.5 million to BioVersys, which is developing an antibiotic to combat a type of bacteria that affects people with compromised immune systems and is increasingly responsible for infections in hospitaliz

Hospitals 101

Hospitals Immunization 101

Fierce Healthcare

JANUARY 5, 2023

How mental health made the 'remarkable transition' to virtual: study. fdiamond. Thu, 01/05/2023 - 15:21.

140

140

STAT

JANUARY 5, 2023

What does 2023 have in store for biotech? How can the FDA win back trust? And who came up with “XBB.1.5”? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into a sweeping congressional investigation into the FDA’s approval of the last treatment for Alzheimer’s disease and what it means for the next one.

FDA 91

FDA 91

Fierce Healthcare

JANUARY 5, 2023

Walgreens, CVS Health say they plan to sell abortion pills following FDA determination. pminemyer. Thu, 01/05/2023 - 16:38.

FDA 124

FDA 124

STAT

JANUARY 5, 2023

More than a year after Al Sandrock was pushed out as Biogen’s R&D chief, the company has set permanent plans to replace him into motion. Biogen announced Thursday that it will be splitting the head of R&D role into two, with Priya Singhal being named as the new head of development. The company has initiated a search for a new research chief, it said in a press release.

87

87

Drug Store News

JANUARY 5, 2023

In addition to an uncertain economy, another contributing factor in the layoffs was the rapid hiring Amazon conducted over the past several years to meet increased demand during the pandemic.

98

98

STAT

JANUARY 5, 2023

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a thick fog enveloping the Pharmalot grounds. After all, as the Morning Mayor taught us: “Every new day should be unwrapped like a precious gift.” So while you tug on the ribbon, we will fire up our coffee kettle to brew another cup of stimulation.

94

94

Pharmaceutical Technology

JANUARY 5, 2023

Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. Under the multi-year strategic partnership, Prevail will detect and advance capsids, which are clinically translatable, along with its cargo to develop the transformative genetic medicines by using Capsida’s novel adeno-associated virus (AAV) engineering platform.

Communication 95

Communication 95

Drug Store News

JANUARY 5, 2023

For the first quarter, sales decreased 1.5% year-over-year to $33.4 billion, while adjusted EPS decreased 30.8% to $1.16, down 29.9% on a constant currency basis.

98

98

Fierce Healthcare

JANUARY 5, 2023

Northern Light Health inks strategic collaboration with Optum. pminemyer. Thu, 01/05/2023 - 15:55.

125

125

Pharmacy Times

JANUARY 5, 2023

Experts outline treatment goals for patients diagnosed with MDS.

138

138

PharmExec

JANUARY 5, 2023

Using market access data from day one of your drug development and commercialization journey puts your brand in the best position to succeed at launch.

98

98

Drug Store News

JANUARY 5, 2023

M&M’s is celebrating women who are flipping the status quo with limited-edition all-female packs featuring its Purple, Brown and Green characters.

97

97

pharmaphorum

JANUARY 5, 2023

Biotech Moderna, Inc. and OriCiro Genomics K.K. have announced they have entered into a definitive agreement for Moderna to acquire OriCiro at a cost of $85 million. The deal marks 10-year-old Moderna’s first acquisition. The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portf

Vaccines 97

Vaccines Immunization 97

Pharmacy Times

JANUARY 5, 2023

The novel antibody will receive expedited review, according to the FDA, and already has market authorization in the European Union.

FDA 132

FDA 132

Fierce Healthcare

JANUARY 5, 2023

Walgreens posts $3.7B loss in Q1 on opioid settlement but boosts sales outlook in 2023. hlandi. Thu, 01/05/2023 - 12:02.

105

105

Fierce Pharma

JANUARY 5, 2023

AstraZeneca, Sanofi tee up 3-way RSV battle in 2023 as FDA signals expedited review for antibody. aliu. Thu, 01/05/2023 - 10:13.

FDA 93

FDA 93

Drug Store News

JANUARY 5, 2023

Mindy McKnight, YouTube star and founder of Hairitage, sat down with DSN to discuss all things beauty and entrepreneurship.

97

97

PharmaVoice

JANUARY 5, 2023

As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

98

98